抗菌药物临床试验结果报告:2017年FDA修正案最终规则下的合规性与时效性分析
本研究基于ClinicalTrials.gov数据,分析2013至2023年间完成的2525项抗菌药物临床试验的结果报告合规性与时效性,比较适用最终规则的ACT与不溯及的pACT。结果显示约80%试验迟报,ACT较pACT报告更及时(HR 1.3),大学资助试验延迟最长。
要点
- 约80%抗菌药物临床试验结果报告迟于联邦截止日期。
- 适用最终规则的ACT报告及时性优于pACT(HR 1.3,95%CI 1.2-1.4)。
- 大学资助试验报告延迟最长,政府资助试验延迟最短。
核心结论
- ACT较pACT报告合规性更高且逾期结果报告延迟更短。
- 仍需更广泛研究以全面评估最终规则的影响。
研究设计与样本
- 从ClinicalTrials.gov提取主要完成日期在2013年5月1日至2023年5月1日间的抗菌药物临床试验数据。
- 最终纳入2525项试验,其中pACT 1769项(70.1%,95%CI 68.2%-71.8%),ACT 756项(29.9%,95%CI 28.2%-31.8%)。
- 分析从主要完成至结果报告的时间,估算风险比比较ACT与pACT的时效性,并评估不同研究类型和资助来源的报告延迟。
主要发现
- 2288项试验(90.6%,95%CI 89.5%-91.7%)在ClinicalTrials.gov报告结果,237项缺失记录中74项(31.2%)可在期刊中找到。
- 总体79.4%(95%CI 77.7%-81.0%)的试验迟报,ACT迟报率71.3%,pACT迟报率82.6%。
- ACT较pACT更可能早期报告结果,风险比为1.3(95%CI 1.2-1.4)。
- 大学资助试验报告延迟最长,政府资助试验延迟最短。
关键数值与推荐
- ACT指受FDA监管且至少有一个美国站点的干预性研究,须遵守联邦报告要求。
- pACT于2017年1月前启动,最终规则要求不适用。
- 最终规则要求指定责任方将结果提交至ClinicalTrials.gov。
临床怎么用
- 临床决策者与研究者需注意抗菌药物试验结果报告普遍延迟,应谨慎依赖未及时更新的注册信息。
- 监管机构应加强执法、简化报告流程并确保及时披露以保障研究诚信。
局限性
- 分析时间线和样本范围存在局限,需更广泛研究全面评估最终规则影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antimicrobial resistance is an urgent global health threat. Timely and complete antimicrobial agent clinical trial results reporting is essential to evaluate the safety and efficacy of investigational therapies. The Food and Drug Administration (FDA) Amendments Act of 2007 mandated results reporting to ClinicalTrials.gov. After nearly 10 years of underreporting, the US Department of Health and Human Services issued the Final Rule, requiring a designated responsible party to submit results to ClinicalTrials.gov. The Final Rule clarified that trials meeting "applicable clinical trial" (ACT) criteria must adhere to the federal reporting requirements. ACTs and probable ACTs (pACTs) are interventional studies regulated by the FDA with at least one site based in the United States. However, pACTs were initiated prior to January 2017, thus the Final Rule requirements do not apply to these trials. This study investigates the effectiveness of the Final Rule by analyzing compliance and timeliness of results reporting of ACTs and pACTs for antimicrobial agents. STUDY DESIGN AND SETTING: We extracted data from ClinicalTrials.gov for trials involving antimicrobial agents with primary completion dates between May 1, 2013, and May 1, 2023. We analyzed the time from primary completion to results reporting and estimated the hazard ratio to compare timeliness between ACTs and pACTs. Additionally, we assessed delays in reporting across different study types and funding sources. RESULTS: Our search resulted in 2793 clinical trial records. After exclusion of ineligible trials, we included 2525 trials. We found 1769 pACTs (70.1%; 95% confidence interval [CI], 68.2%-71.8%) and 756 ACTs (29.9%; 95% CI, 28.2%-31.8%). Among the 2525 eligible trials, 2288 trials (90.6%; 95% CI, 89.5%-91.7%) were reported on ClinicalTrials.gov and 74 out of the 237 (31.2%) missing records were found in journals. Overall, 79.4% (95% CI, 77.7%-81.0%) of trials were reported late (71.3% of ACTs vs 82.6% of pACTs). ACTs were more likely to report results earlier than pACTs, with a hazard ratio of 1.3 (95% CI, 1.2-1.4). CONCLUSION: ACTs demonstrated greater reporting compliance and shorter delays in the reporting of overdue results. While this analysis provides initial insights, limitations related to timeline and sample scope suggest that broader investigations are needed to fully evaluate the impact of the Final Rule. PLAIN LANGUAGE SUMMARY: Antimicrobial resistance is an urgent global health threat, resulting in an estimated 5 million deaths globally in 2019. The pipeline for new antimicrobial agents is shrinking, with only six agents in clinical development meeting at least one of the World Health Organization's criteria for innovation in 2021, and resistance to new products emerging on average within 2-3 years of market entry. Researchers depend on timely, high-quality clinical trial data to build the evidence base needed to combat this threat. However, late and incomplete reporting of trial results to ClinicalTrials.gov, the United States federal trial registry, undermines that effort. The FDA Amendments Act of 2007 and the subsequent 2017 Final Rule established reporting requirements and penalties for noncompliance, yet adherence remains poor. In this study, we analyzed 2525 antimicrobial agent clinical trials completed between 2013 and 2023 to assess how these policies affect reporting compliance and timeliness. We found that around 80% of trials reported results late, and trials with outstanding results had a median delay of around 6 years past the federal deadline. Although 93.5% of trials had ultimately results submissions through ClinicalTrials.gov or journal publications, these delays limit the ability of clinicians, policymakers, and researchers to make timely decisions. Trials subject to the Final Rule reported results significantly faster than comparable earlier trials, with a 30% higher rate of reporting over time, suggesting that clearer regulatory guidance improves compliance. Reporting timeliness also varied by funding source: university-funded trials had the greatest delays, while government-funded trials had the shortest. As of March 2026, over $100 billion in potential fines remain unclaimed despite 22% of all registered trials having outstanding results, and no penalties have ever been imposed. Strengthening enforcement, simplifying reporting processes, and ensuring timely disclosure are critical to safeguarding research integrity and accelerating the development of effective antimicrobial treatments.
引用
- Curtin M, Wiltshire A, Nilsonne G, et al. Results reporting in antimicrobial agent clinical trials: an analysis of compliance and timeliness under the 2017 FDA Amendments Act Final Rule. J Clin Epidemiol. 2026. PMID: 42082083. doi:10.1016/j.jclinepi.2026.112307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。